Looking ahead Disney has both the recovery stock and the tech stock stories going for it. Jumped 5% on the streaming news but still below precovid highs, I feel once we get post covid this will go on a big run.Disney going all in with streaming and DTC.
Disney says its 'primary focus' for entertainment is streaming — announces a major reorg
Disney is restructuring its media and entertainment divisions, as streaming becomes the most important facet of the company's business.www.cnbc.com
Disney content is unmatched and with its streaming service, it can control its distribution. Pretty good combo!
2019 "parks experiences and products" was around 40%. That does include products which may or may not be sold in the parks so a little muddy there, but it's a huge # nonetheless.
www.statista.com
Mulan is a niche movie and wasn't going to do too well in US theaters anyway (essentially made for the Chinese audience). Put the next Avengers or SW movie on Disney+ and then we will see how successful the platform is.2019 "parks experiences and products" was around 40%. That does include products which may or may not be sold in the parks so a little muddy there, but it's a huge # nonetheless.
Disney revenue by segment 2023 | Statista
Disney's revenue breakdown shows that the Media and Entertainment segment generates the largest portion of revenue for the company.
And they are getting hurt by the inability to put movies into theaters. They went direct to Disney+ with Mulan and didn't do so hot with that. Now maybe that changes in time, and 5 years from now movies will do better going direct to Disney+ but right now the lack of theaters is restricting revenues.
Do note that the mix was a bit different in 2016, but I think that speaks to the slow demise of cable TV and again points to the need to go direct to consumer digitally.
Hearing positive sentiment on buying Gilead as a trade vehicle as it currently sits near a support level that dates back a few years. Don't know about it as a long term investment, but from my superficial view point, looking at rev's over the past 5 years I'm not seeing it.
I dunno, I felt the hype was pretty big. Granted I've always loved Kung Fu flicks so maybe my glasses were colored.
I wonder about Gild's remdesivir. Still did not show up in revenue's as of the last quarter, and with the concern with many Covid drugs(not sure about Gild's) is that it might be a rev driver but not an earnings driver.
FSLY had crossed over $130 just yesterday but tanks 30% in after hours today on news it is not used as much as expected by Tik Tok.
It’s ridiculous how high it’s gone.
Let's say it gets back into the $70's as Cramer thinks it might, would you get back in?It’s ridiculous how high it’s gone.
Fastly is a buy if the stock continues to tank on guidance cut, Cramer says — CNBC
"The fact is this is a wild trader that was due for big sell-off anyway," CNBC's Jim Cramer said. " "Now the stock has been significantly de-risked ... and I actually like it more."apple.news
for a buy and hold guy, you sure spend a lot time tracking the market.
Need to track to see what is best to buy and hold. :)
To that point Russel 2k was up 1% today.
You can see from my data above, R1K and R2K have the same return since end of August. R2K Growth is starting to pop, so I will keep an eye on that.
yes, I get the rebalancing but it's still not everyday. I ran my Q3 numbers and I'm up 5.5% YTD now.
I preface this still saying GE is likely to be a slog but some positive news in the last couple weeks for GE. GS came out with an upgrade a little while back saying it thinks the worst is behind it and 50% upside is possible. Like I said above high single digits/low double digits is quite realistic if cash flow picture improves with time. Also saw this morning Boeing 737 Max is getting clearance by European regulators for safe travel so a positive sign for GE Aviation segment. So air travel still has a ways to pick up even though it's improving and cash flow needs to get better but some positive signs.
It's a "fake study". Not a legit double blinded well controlled FDA approved study.Not particularly good news for GILD and remdemsivir.
Big global study finds remdesivir doesn't help Covid-19 patients | CNN
Remdesivir has "little or no effect on mortality" for patients hospitalized with coronavirus and it doesn't seem to help Covid-19 patients recover any faster, either.www.cnn.com
I wouldn't call it a "fake study" but it's not the end of story either. On balance I still think the news on remdemsivir is positive but I wouldn't throw out something like this as well. I don't follow GILD closely but actually it doesn't even sound like this WHO study contradicts GILD's own study. The results sound kind of similar to me. GILD's own study says it's effective at certain earlier stages in the disease progression but saw nothing significant when you take mortality across a range of patients from all stages of disease progression. That to me sounds exactly like the results of the WHO study. So actually doesn't sound like they're in conflict with each other really because the WHO study is taking a randomized group from all stages of disease progression.
Sorry, the WTO study is garbage compared to the real FDA study. Stick with those results and don't get confused. Smart investors know this, which is why the stock is essentially unchanged. However, the general public is less smart.
Just how much are sales of remdesivir going to be and will it meet expectations.
www.reuters.com
Interesting note on GE. I guess they still make engines for Boeing.Just how much are sales of remdesivir going to be and will it meet expectations.
Looking at a chart it does seem like it has some support in the low 60s area but it also just got rejected by the 50DMA around 65. If it doesn't report strong sales of the drug not sure if it will have much momentum to break through that.
Analysis: Sales of first big COVID-19 drug, remdesivir, may disappoint
Investors betting on big profits from COVID-19 treatments may get an unwelcome surprise when Gilead Sciences Inc <GILD.O> reports quarterly results this month. Its remdesivir, the first important coronavirus treatment, has not been used as much as first expected and faces...
Side note on GE....looks like it's having a good day up 6.5%...I'm guessing on the positive 737 Max news I posted about earlier.
They make engines for both Boeing and Airbus but Boeing is a bigger customer I believe.
Tough to track for me (due to numerous accounts). Looks like we are up 9-10% YTD. Much is this return is due to our focusing more on growth ETFs/funds. This is just our investments. If you look at all liquid assets and our cash, this # goes down a bit.
Not particularly good news for GILD and remdemsivir.
Big global study finds remdesivir doesn't help Covid-19 patients | CNN
Remdesivir has "little or no effect on mortality" for patients hospitalized with coronavirus and it doesn't seem to help Covid-19 patients recover any faster, either.
I didn’t see the article to which you referred. Not sure if you didn’t link it.
